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Abstract 
Background:  
Point of care (POC/ near patient) testing for measurement of the 
international normalized ratio (INR) is a technical advance with 
claims of increased utility and better patient outcomes. This has also 
been reported to be useful in inpatients to improve time to 
intervention.  This study evaluated the accuracy and precision of the 
coagulation monitoring system (INRatio) for the determination of 
INR compared with an established laboratory method for reducing 
patient treatment time in the outpatient setting in vascular surgery. 
 
Methods: 
A prospective case control design was used to study all patients on 
oral anticoagulation managed in the Vascular Surgery outpatient 
clinic.  Patients with anemia, haemolysis or lupus anticoagulant 
positivity were excluded from the study.  The POC test result was 
compared to the reference lab test to check for statistical and clinical 
correlation. Sample size was calculated based on published literature 
with a test sensitivity of 87.5%; precision 5% and desired confidence 
level 99%. 
 
Results:   
There were 168 patients tested; 55% were male, the mean age was 
45.4(Range 20-75).  All patients tested were on anticoagulation with 
a target INR range of 2-3; 93% were under treatment for DVT and 
7% for arterial disease.  60% of the study population was in the target 
INR range. Tests were done for statistical and clinical correlation. 
The INR range obtained by using the test machine was 0.8-7.5 
(reference lab 0.8-10), mean INR was 2.22+/- 1.6 (test machine) 
compared to 2.46 +/- 1.3 (reference lab).  The mean absolute 
difference was 0.79 +/- 0.92 and the mean relative difference was 
8.1% +/- 1.03. Data was analyzed using a Bland-Altman plot yielding 
a mean of 0.738 (SD 0.92) Concordance between the tests was 75% 
with r
2
= 0.52 on linear regression.  Using an error grid plot, excellent 
clinical correlation was seen in 63.8%. In 5.4% a major corrective 
action was needed but potentially missed if relying on the test 
machine. 
 
Conclusion:  
This test achieved only moderate statistical and clinical correlation.  
In the presence of a good reference lab, this POC test cannot replace 
the lab test and hence cannot be used in shortening patient treatment 
time.  The accuracy of the machine is moderate therefore it has 
potential utility where access to a reference lab is difficult. 
Introduction 
 
Vitamin K antagonist are oral anticoagulants which reduce 
thromboembolic events; clinical outcome being better when 
patient’s international normalied ratio (INR) is maintained in 
a narrow therapeutic range.  This requires regular testing with 
well timed dose adjustments. Accurate point-of-care devices 
which provide reliable INR results allow self-testing at the 
patient’s home. This result is then managed by the patient’s 
physician or patients interpret their INR to adjust their 
medications (self management). Self-monitoring has been 
demonstrated in systemic reviews to be safe, helping to 
reduce thromboembolic events, reducing the risk of death and 
major bleeding especially in specific populations (elderly). 
Patients spend more time in the therapeutic range of INR.  
However use of self-testing and self-management differs 
considerably between countries.  
At initiation of oral anticoagulation, INR has to be tested 
once every three days till it reaches the target level(2-3) after 
which it can be tested once every week for 2 weeks. If 
consecutive INR’s remain in the therapeutic range for the first 
month, testing intervals can be longer apart.(1)    Some 
patients may need treatment lifelong- in these patients, testing 
at least once every two months is required.  This requires the 
patient to give the blood test in the morning of the planned 
OPD visit.  Many patients are not from the same city and 
reaching the hospital in time to give the blood test is difficult.  
The test is often not ready by the time the patient is seen in 
OPD.  This delay is inconvenient both for the patient and the 
treating doctors. It often necessitates a full day spent at 
hospital which implies loss of wages.  Patients who do not 
stay in the same city may need to stay overnight which is 
even more disruptive to their routine life.  If the INR is low 
(hypocoagulable), medications have to be increased.  If INR 
is high (hypercoagulable), the patient might be at risk of 
bleeding and mediations have to be decreased.  The INRatio 
Prothrombin Time Monitoring system is one of the available 
point of care instruments for home testing of INR.  It has 
demonstrated very good accuracy, precision and technical 
reliability for self monitoring by patients. (2)  These 
machines have been in use in other countries USA, Germany, 
France (3–5) with a backup physician support system. One 
study in an internal medicine academic clinic showed that use 
of such a point of care testing can also markedly improve the 
time to intervention in a hospital setting. (6)   We studied this 
machine for a similar application in a Vascular Surgery unit 
for shortening treatment time. 
 
 
 
 
 
 
Patients and methods 
 
Objectives of the study  
1. To evaluate the accuracy and precision of the INRatio 
point of care anticoagulant monitor system to determine the 
INR compared with a established laboratory reference. 
2. To determine if this system helps in reducing patient 
treatment time in the outpatient and inpatient setting in 
vascular surgery. 
 
Study population recruitment 
   
All patients undergoing INR testing in Vascular Surgery OPD 
are enrolled in the study.  Those patients with lupus 
anticoagulant positivity, those on heparin/low molecular 
weight heparins, anemia, or haemolysis were excluded. Data 
was collected in the Vascular Surgery OPD. Sampling was 
done for consecutive patients / INR’s; data collection was 
prospective, selection was independent of the results of the 
index test. The entire sample was verified with the reference 
standard of diagnosis.  Basic patient details like indication for 
anticoagulation, patient age, sex were also documented.  
The blood collection was done by the principal investigator 
after informed consent. The time period between the index 
(POC) test and the reference standard was less than 3 hours 
and this was unlikely to change the target health condition 
between the two tests. The index test was interpreted 
independently of the reference standard and without 
knowledge of the result of the reference test.  
 
Sample size calculation was based on the study Taborski U, 
Braun SL et. Al ; the POC had a sensitivity 87.5 % for a 
precision of 5 % and a desired confidence level 95% ; the 
calculated sample size was 168. The test results were not 
interpreted using clinical data from participants. Un-
interpretable test results were excluded from the final 
analysis.  The numbers of these were noted as machine 
failure.  There was no missing information. 
 
 
Results and Discussion 
 
There were 168 tests done, results were obtained in 149 
patients. In 11%, the test result was not obtainable as the 
result reported was an “error”.The age range of the patients 
tested were 22-75 with an average range of 45 years.  There 
were 75 females. the most common indication for 
anticoagulation was deep vein thrombosis. Only 60% of the 
patients reached target anticoagulation levels during the study 
period. The range of INR detected in the tests was 0.75 to 10 
both for the laboratory and INRatio.  These results are 
represented in Table.1 
 
 
  
Table.1: General characteristics of patients 
 
General characteristics N= 168 
Male  55%  
Mean age   45.4 
Diagnosis  DVT  93% 
Arterial Disease 7%  
Target INR  2 to 3  
% population in Target  INR 
range  
60  
 
 
 
 
 
Statistical analysis 
 
The mean INR WAS 2.46 with a standard deviation of 1.3 
when checked in the lab. The INRatio monitor yielded mean 
values near 2.22 with a standard deviation of 1.6. The range 
of INR measured in both machines covered the clinically 
relevant range from the 0-10 which reflected that the test 
machine also picked up the patients who were out of the 
therapeutic range.  
 
The mean absolute difference [INR reference – INR self-
monitoring] and the (MRD) relative difference ([INR 
reference – INR self-monitoring] / INR reference) for the 
whole group of data, mean   The Hill accuracy rating of the 
MRD% is very good (6.58–9.25), good (9.32–11.86), 
acceptable (11.93–14.54), marginal (14.60–20.28) and very 
poor (20.34–26.99). The mean absolute difference was 0.79 
+/- 0.92 and the mean relative difference was 8.1% +/- 1.03 
which was in the very good range indicating that the 
differences in the test results from both the machines show 
good concordance.  
 
 
 
 
 
 
 
 
 
 
\ 
 
 
 
 
Table 2: Basic statistical comparison 
 
 
 
 
 
 
 Reference 
Lab  
INRatio  
INR  Mean +/-SD  2.46 +/- 
1.3  
2.22+/- 
1.6  
INR range  0.8-10  0.8-7.5  
Mean absolute 
difference  
0.79 +/- 0.92  
Mean relative 
Difference  
8.1% +/- 1.03  
The clinical and biological validity of the results were then 
analyzed by using a Bland Altman plot. The difference of 
results of the two methods were plotted against their average, 
this represents the limit of agreement among the two 
techniques and the difference of the averages ± 1.96 standard 
deviation (SD).   We also calculated the Passing and Bablok 
linear regression which demonstrated agreement of methods 
(slope and coefficient of correlation). The concordance 
correlation coefficient was also calculated to assess the extent 
to which observations fall on the 45º line through the origin. 
The Pearson correlation coefficient-  a measure of precision –
to study how much every observation deviated from the best 
fit line; was calculated.   Cb was also measured, this was a 
bias correction factor that tested how much the best fit line 
differred from the 45º line that passed the intersection of the 
axes and thus was also an estimate of accuracy. 
The Bland and Altman plot (Fig. 1) is a graph representing 
the difference (bias) when comparing the average of the two 
measurements: INRatio and the laboratory reference.  A 
visual inspection disclosed a trend good agreement between 
the two machines with very few values lying outside the 2SD 
mark even when the INRvalues were in the higher range. The 
linear regression revealed a moderate deviation from the best-
fit line with a slope of 0.7. This was confirmed by a 
concordance correlation coefficient of 0.52 at a significance 
of 0.01.   The concordance coefficient was 75%.   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 3: Lab- machine concordance 75.2%  
 
Reference  Lab test  
Total  Hypo  Normal  Hyper  
Test 
machine 
INR  
Hypo  45  7  2  54  
Normal  10  41  5  56  
Hyper  3  10  26  39  
Total  58  58  33  149  
 Figure 1. Bland Altman plot 
 
 
 
 
 
 
 
 
Figure 2: Regression analysis 
 
 
 
 
 
 
 
The next section of the analysis dealt with formulating an 
error grid plot based on the clinical ranges of significance.  
This assessed the short term effect of a erroneously high or 
low result on the clinical decision.  The grid assessed the 
percent of patients who were at risk of receiving an incorrect 
dose if the test machine INR was used.  This yielded a result 
of only 70 % being in the best fit zone.  5% of patients would 
be in the clinically dangerous zone where they would risk 
over or under anticoagulation and thus be at risk for bleeding 
or thrombotic complications.  In 30%-which was a 
significantly large proportion, the test results did not 
correspond to the lab values.  This is similar to reports from 
other studies- the interpretation of this has been different 
though.  As they are not in the clinically dangerous zone, 
more frequent retesting often brings these patients into the 
best fit zone.  However if the machine is being used instead 
of the lab standard, the test results would be “inaccurate” in 
30% - this is not clinically acceptable.   
Hence the conclusion would be that in the absence of the 
testing facilities or a lab standard, there is potential utility of 
the INRatio machine as a means of alternative testing ; but in 
centres with a certified lab the lab results would be superior 
in clinical management. 
As the machine overall had poorer clinical utility; the 
secondary objective of the machine being able to shorten 
treatment times cannot be assessed.  
 
 
 
 
 
 
 
 
 
 
Table 4: Error grid plot results 
Legend  Clinical implication  Percent 
results  
Zone A  Clinical decision same, 
difference in values 
clinically irrelevant  
63.8  
Zone B  Corrective action in the 
same direction, 
inadequate but clinically 
irrelevant  
21.4  
Zone C Corrective action 
necessary but not taken, 
clinically relevant  
9.4  
Zone D  Dangerous situation as 
major corrective action 
needed but missed  
5.4  
 
The cost of both tests were similar- the new test being 
marginally more expensive, the cost of the Reference lab test 
in our setup is 220INR – the breakdown of costing for the test 
machine is  depicted in Table 5. 
 
Table 5: Cost accounting 
 
Sl no. Cost (Rs/-)  
INRatio machine 17850  
Test strips(291) 48 strips cost 8064/- 
4 boxes needed 
28224  
Misc(batteries)  100  
Total  46174  
Cost per patient  274  
 
 
 
 
Literature review 
 
Treatment with acitrom or warfarin (oral anticoagulants) as is 
required for various clinical conditions. Long term oral 
anticoagulation therapy is commonly prescribed following 
artificial cardiac valve placement,  atrial fibrillation or venous  
thromboembolic disease. Regular monitoring for the 
prothrombin time and the international normalized ratio 
(INR) reduces the incidence and risk of bleeding and 
thromboembolic events. Strict adherence to the small 
therapeutic range is difficult; overdosing or under treatment is 
frequent with adverse clinical outcomes. Monitoring is 
usually managed by general practitioners; some centres have 
speciality anticoagulation clinics or hemostasis units. The 
coagulation cascade depicted in Figure 1 is tested by various 
tests of anticoagulation- these are classified as in the 
following table. (Table 4) 
Table 6. Tests of coagulation 
Screening tests 
PT/ INR 
 PTT 
 Thrombin time 
 Fibrinogen 
 Factor assay 
Chromogenic factor assays  
Factor VIII , Inhibitor assay 
Von Willebrand factor assay 
Platelet function test 
Light aggregrometry 
Nuclear assay 
PFA-100 analysis 
Flow cytometry 
Prothrombotic workup 
Anti-thrombin  
Protein C assay 
Protein S, APC resistance  
Homocysteine 
Antiphospholipid assay 
Fibrinolsis tests 
D- dimer 
Plasminogen 
Lupus anticoagulant 
Gene test Fac V, II- G20210A mutation 
Miscellaneous 
ACT 
ADAMTS 
Bleeding time 
Ecarin clotting time 
Anti Xa / thrombin generation tests   
Thromboelastogram 
Heparin induced thrombocytopenia 
assay 
 
The classical coagulation cascade was studied as the extrinsic 
intrinsic and common pathways but we know that these do 
not function separately. These are now being studied as 
extrinsic tenase, intrinsic tenase and prothrombinase. 
 
 
 
 
Figure 3: Coagulation Cascade 
 
 
 
 
 
 
 Figure 3: Coagulation Cascade: current understanding 
 
 
 
 
 
 
 
Different coagulation tests study different aspects of this 
complex in- vivo coagulation system.  The prothrombin time 
was initially described by Quick in 1935.  This is the time in 
which a fibrin clot forms after adding tissue factor 
(thromboplastin), phospholipid and calcium to decalcified, 
platelet poor plasma.  Thromboplastin or tissue factor(TF) is 
a substance found in plasma that converts prothrombin to 
thrombin. They used to be extracted from rabbit brain or 
other organs and also contained phospholipids. These are 
species specific. Modern laboratories use recombinant human 
TF. This is re-lipidated to provide phospholipid.  
The PT depends on the levels of functional/active factors of 
the extrinsic and common pathway. The factors tested are 
Factors VII, X, V, II and fibrinogen. The clotting cascade is 
depicted in the diagram below. Other than laboratory factors, 
there are pretesting variables which can affect the result of the 
PT.  
At 37°C, platelet poor plasma is mixed with thromboplastin 
and an excess of calcium chloride (25mM) is added. The time 
from addition of calcium to formation of  a fibrin clot is the 
PT. It can be detected manually or by an automated system. 
Abnormalities of this test can occur in a variety of conditions. 
This is represented diagrammatically in the following figure, 
Various factors can affect the PT and these are listed in Table 
7.  Other than this , patient factors, pretesting factors and test 
reagent factors can also affect the test- these are discussed in 
the subsequent sections. 
 
 
 
 
 
Figure 4: Prothrombin time – the test  
 
 
  
 
 
Table 7. Factors affecting PT 
PT alone increased Factor VII deficiency 
Increased PT + aPTT deficiency of Vitamin K 
 antagonist to Vitamin K  
  liver disease 
 other coagulation 
abnormalities 
 malabsorption 
 Unfractionated heparin, Direct 
thrombin inhibitors 
 clotting factor deficiencies 
  VKORC1 gene mutations 
 Dilutional coagulopathy 
 Lupus anticagulant 
Decreased PT Administration of rVIIa 
  
  
Pre-analytical variables, quality control, external quality 
assurance are important for results that are reliable, 
reproducible and accurate. These are listed in the following 
table. 
Table 8: Other factors affecting PT 
Physiological variables Pathological states 
Technique of phlebotomy Volume of sample 
Proper collection tube  Adequate storage 
Proper handling Avoid undue agitation 
Proper centrifugation Correct transport conditions 
Avoid delays in processing  
 
Correct identification, 
labeling 
 
 
 
There are many physiological differences between patients. 
These may sometimes be outside of lab control but being 
mindful of them can help in minimizing lab result variations 
by either ensuring proper handling or reagent use. Some of 
these other variables are 
1. The vitamin K dependent clotting factors are low at birth  
reach adult values at six months of age. They may reduce in 
old age as well. 
2. Pregnancy changes the composition of body fluid 
compartments and causes a thrombophilic state with  increase 
in the levels of FacVIII, vWF, Fac II, Protein S and fall in 
platelets 
3. High bilirubin orhyperlipidemia  forms a turbid plasma – 
this does not allow proper functioning of the optical density 
analyser. 
 
The reference range can vary due to changes in the source of 
Tissue Factor ( human, rabbit) ;  automatic or manual- 
method of testing; optical/ mechanical method of end-point 
determination . Each laboratory sets up a normal range but 
usually, the normal plasma prothrombin time is between 13-
15 seconds. 
The differences of sensitivity is the sensitivity index. 
Different thromboplastins are calibrated against al WHO 
International Reference Preparation ( IRP). This provides a 
International sensitivity index or ISI. Human brain extract 
was used initially- adsorbed bovine plasma was added – this 
optimised the content of non-vitamin K dependent 
coagulation factors. Subsequent WHO IRPs contain no 
adsorbed bovine plasma. The WHO reference thromboplastin 
has an ISI of 1.0. 
The calibration of a thromboplastin is against a reference of 
the same species. Prothrombin Time is performed in duplicate 
for each thromboplastin .  Following this the mean for each 
pair is calculated. 20 normal donors not on anticoagulants and 
60 patients on oral anticoagulants for 6 weeks or more are 
tested. A less than 10% difference among duplicate samples 
is acceptable, otherwise , the test needs repeating. 
Using a double-log paper these results are plotted.  The 
reference sample is plotted on the Y axis and the test plasma 
is plotted on the X-axis. The slope of the line of best fit is the 
international sensitivity index. A good thromboplastin has a 
ISI near 1.0.  A high ISI makes the thromboplastin less 
sensitive to minimal changes PT. 
The International Reference Thromboplastin standardizes the 
test. However different machines (coagulometers ) use 
different methods of end-point detection  leading to a lot of 
variations of PT. Hence a local calibration of thromboplastins 
is recommended.  It is advisable to test batches of plasma 
samples with known INRs against a laboratory-specific 
thromboplastin with the coagulometers which will be used to 
derive the PT. 
The INR is the ratio of a test sample compared to a normal 
PT (derived from the log mean normal prothrombin time 
from normal donors) corrected to the thromboplastin 
sensitivity. 
 A nomogram correcting PT ratio to INR can be used for any 
thromboplastin with a known ISI.   
The INR value for a patient not on vitamin K antagonist 
should be 1.0. The therapeutic range for anticoagulation 
varies according to the indication.. 
 
 
 
 
International Normalized Ratio (INR) or prothrombin time 
self monitoring devices, are battery-operated devices for use 
by patients at home to monitor and dose adjust oral 
anticoagulant therapy. Self-monitoring permits frequent 
measurement and self-management increases the time that 
anticoagulation is within a therapeutic INR range while 
decreasing the incidence of thromboembolic or hemorrhagic 
events. This is considered medically necessary if long term 
anticoagulation with frequently determination of INR values 
is required and the treating physician prescribes home testing. 
In the context of self-monitoring many INR measuring 
devices have been developed. 
The CoaguSense™ Self-Test PT/INR Monitoring System 
(CoaguSense, Inc., Fremont, CA), ProTime
®
 
Microcoagulation System (International Technidyne 
Corporation, Edison, NJ), CoaguChek
®
 XS System for 
Patient Self-Testing (PST) (Roche Diagnostics-North 
America, Indianapolis, IN), CoagCare
®
 (ZyCare
® 
Inc, Chapel 
Hill, NC), and Alere™ INRatio®/INRatio2® PT/INR 
Monitoring Systems (Alere Inc., Waltham, MA)  are 
approved for use by the (U.S.) Food and Drug Administration 
(FDA) . The prescribing physician is responsible for the 
training and ongoing management of individuals selected for 
self-monitoring. 
The machine used in this study is INRatio.  INRatio2 is the 
newest coagulation monitor manufactures by HemoSense. 
 
 
 
 
 
 
 
Figure 5: INRatio monitor 
 
 
 
 
Testing. INRatio2 yeilds Prothrombin Time (PT) and 
International Normalized Ratio (INR) results in less than a 
minute using 1 drop of blood from a fingerprick. It is easy to 
use, and has integrated quality controls with every test. 
It does not need for external liquid quality control or extra 
strips or separate device to check electronic controls. Test 
Strips do not require refrigeration, are individually wrapped 
The device has a single button operation,  1 step auto turn-on 
with strip insertion, large LCD screen, easy to read digits,  
icon based interface and long battery life. 
A Test Strip is inserted into the INRatio2 monitor,  a drop of 
fresh whole blood from a fingerstick is applied to the test 
strip and the monitor performs the PT and  2 quality control 
tests (normal and therapeutic) simultaneously, and determines 
whether the controls are within 
preset limits. If they are, strip integrity is verified, and the 
monitor reports the PT test result. If they are not, the monitor 
displays an ERROR message. 
The machine is 5.9 inches (15.1 cm) in length, 2.9 inches (7.4 
cm) in width; 1.8 inches (4.6 cm) in height; 9.3 oz. (263 g) 
weight. 
 
 
 
 
 
 
 
 
  
 
Figure 6: Method of testing 
 
 
 
The blood is drawn into the test area by capillary action 
where it mixes with reagents that cause coagulation.  
 
Figure 7: Test strip mechanism 
 
 
 
 
 Figure 8: Test strip parts 
 
 
 
 
 
 
 The test results are displayed in less than 60 seconds. The machine 
performs electronic system self-test automatically.  
 
Figure 7: Test strip quality control 
 
 
 
The system is self-maintaining, only routine cleaning is 
needed. It has a simple interface which can record change of 
time, date, and the result. It uses 4 AA batteries or optional 
power adapter as a power source. It can store up to 60 test 
results in memory. It has a built-in port for printing / 
electronic communication.  
INRatio detects clotting by measuring change of the electrical 
impedance of the sample of blood occurring with the 
conversion of fibrinogen to fibrin.  The PT microcoagulation 
pump agitates the sample till clot formation. This is followed 
by optic detection of the reduction of motion in the blood as it 
clots. Magnetic alternating fields are used in the Coagucheck-  
iron particles on the sample strip move ; at the time the blood 
clots, the movement of blood particles stops and this is read 
by the machine. Different machines detect clotting by 
mechanical (AMAX) or optical methods (ACL, MLA, STA, 
Sysmex) when using plasma. 
Figure 9: Mechanism of testing INR 
 
 
 
 
 
 
 
Figure 9: Mechanism of  generation of INR 
 
 
 
 
 
 
 
Use of prothrombin time self-monitoring devices are effective 
in maintaining the INR values within a therapeutic range with 
improved anticoagulation control. This improvement is 
thought to be due to several factors but most importantly due 
to more frequent testing intervals. The complications 
associated with self-monitoring are similar to what is 
associated with monitoring by a physician or a specialized 
clinic. With  proper training and support a home testing 
device is accurate, feasible, and possibly more effective than 
standard laboratory prothrombin time testing in maintaining 
anticoagulation control within target therapeutic ranges for 
conditions requiring long-term anticoagulation. 
The FDA approval of home prothrombin time self-monitoring 
devices is based on the demonstration that home prothrombin 
monitors produce results similar to laboratory-based 
measurements.  Effective March 19, 2008, the Centers for 
Medicare and Medicaid Services (CMS) , USA, implemented 
a National Coverage Determination (NCD) for Home 
Prothrombin Time Monitoring for Anticoagulation 
Management. 
A Cochrane meta-analysis (Garcia-Alamino, 2010) reported 
on a pooled estimate of 18 randomized controlled trial (4723 
participants), showing significant reductions in both 
thromboembolic events (risk ratio [RR] 0.50, 95% confidence 
interval [CI] 0.36 to 0.69) and all-cause mortality (RR 0.64, 
95% CI 0.46 to 0.89). Trials of self-management alone 
showed significant reductions in thromboembolic events (RR 
0.47, 95% CI 0.31 to 0.70) and all-cause mortality (RR 0.55, 
95% CI 0.36 to 0.84); self-monitoring did not (thrombotic 
events RR 0.57, 95% CI 0.32 to 1.00; mortality RR 0.84, 95% 
CI 0.50 to 1.41). Self-monitoring significantly reduced major 
hemorrhages (RR 0.56, 95% CI 0.35 to 0.91) while self-
management did not (RR 1.12, 95% CI 0.78 to 1.61). Twelve 
trials reported improvements in the percentage of mean INR 
measurements in the therapeutic range. No heterogeneity was 
identified in any of these comparisons. The authors concluded 
that compared to standard monitoring, individuals who self-
monitor or self-manage can improve the quality of their oral 
anticoagulation therapy. The number of thromboembolic 
events and mortality were decreased without increases in 
harms. However, self-monitoring or self-management were 
not feasible for up to half of the individuals requiring 
anticoagulant therapy due to refusal to participate, exclusion 
by their general practitioner, and inability to complete 
training. 
Bloomfield and colleagues (2011) published a meta-analysis 
and systematic review that included randomized controlled 
trials in adults comparing home monitoring to monitoring in a 
medical centre; the studies included adults on long-term 
(greater than three months) therapy. The systematic review 
included 22 trials; five on self-monitoring; 14 including self-
management. There were significantly fewer major 
thromboembolic events in the self-monitoring and self-
management group- pooled analysis- (99 of 4004 subjects, 
2.5%) in contrast to the standard treatment group (149 of 
3755 subjects, 4.0%; odds ratio [OR]: 0.58 (95% CI: 0.45 to 
0.75). Major bleeding event rate did not differ significantly 
between the groups. Similar to the Cochrane meta-analysis 
(Garcia-Alamino, 2010), There was a very low rate of study 
participation in subjects who satisfied the eligibility criteria. 
There was no separate analysis of studies with respect to 
enrollment of inception cohorts. 
Heneghan in 2012 published a meta-analysis using a design 
like the other published metaanalyses. They searched for 
randomized controlled trials comparing management of oral 
anticoagulation in adults to physician management. This 
review did not discuss whether home monitoring was used in 
the initial three months of anticoagulation therapy. The meta-
analysis included data of 6,417 participants from 11 of the 
21suitable trials. In a pooled analysis, there was a statistically 
significant reduction in the thromboembolic event rate in the 
home monitoring group compared to the standard therapy 
group (hazard ratio [HR]: 0.51, 95% CI: 0.31 to 0.85). There 
was no significant difference in the major hemorrhagic event 
rate (HR: 0.88, 95% CI: 0.74 to 1.06) or death rate (HR: 0.82, 
95% CI: 0.62 to 1.09). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
• INRatio accurate for INR testing in an OPD setting only when 
no reference lab available 
• Has moderate overall utility 
• Strict clinical agreement not adequate 
• Effect in shortening treatment time in our setting not relevant 
• No conflict of Interest 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
1. Informed consent form  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                         PATIENT INFORMATION SHEET  
 
1. Study title 
Analytical performance of a coagulation monitoring system INRatio for the 
determination of INR compared with an established laboratory method and its use in 
shortening patient treatment time in a tertiary care vascular surgery centre. 
 
2. Principal Investigator  Dr. Indrani Sen 
3. Contact address    
Department of Vascular Surgery, Christian Medical College, Vellore 632 004, 
India 
 Email: dr.indranisen@gmail.com  
Tel. + 91 416 2282085 
 
This study is a research project conducted in CMC Vellore, departments of 
Vascular Surgery and Transfusion medicine and immunohaematology. You 
know that while you are on blood thinners you routinely give a blood test 
(international normalized ratio- INR) which you require as part of the standard 
outpatient procedure for treatment.  
We want to study a machine for testing INR and see if this will help to get an 
accurate test result faster than testing in the lab. If you decide to participate in the 
study, you will be asked to give one drop of blood from a finger prick test. This 
is the only invasive procedure that you will be subjected to.  We will compare 
the result of this test to the test you have given in the lab to see if both the results 
are similar.   
 
All precautions necessary will be taken to avoid any complications that may arise 
due to the finger puncture.  Your finger tip will be cleaned with spirit and left to 
dry. Puncture will be made into the finger tip using a fine needle and a small 
amount of blood will be collected onto a testing strip. Compression will be 
applied for 2 minutes to ensure that bleeding has stopped. This is all done as a 
one time process. Your treatment will be based on the lab test result- the finger 
prick test result will not be used. 
 
By participating in the study you will not be made to incur any added expenses. 
There is no added risk of any kind for you by participating in this study. The 
information generated by this study may not directly benefit you at this time but 
may benefit later in reducing the waiting time for the blood test result. Any 
personal information about you that is collected as part of this study will be 
maintained strictly confidential. 
 
If you have any queries or problems you can contact the principal investigator at 
the above address.  If you choose not to participate, it will not affect your 
treatment in any way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT DOCUMENT 
 
 
I  …………………………….( Participant’s name), Hosp 
no…………… have fully read and understood the participant’s 
information sheet as given above. 
 
By signing this form I agree that 
 
(1) I understand that the purpose of this study is to improve the 
quality of medical care and that my involvement may not 
benefit me. 
(2) I have been made aware of the procedures involved in the 
study and the expected inconvenience, risk, discomfort or 
potential side effects as far as they are currently known by 
the researcher. 
(3) My participation in this study is fully voluntary and that I 
am free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
(4) I understand that my identity will not be revealed in any 
information released to third parties or published. 
(5) I will not restrict the use of any data or results that arise 
from this study provided such a use is only for scientific 
purpose(s) 
 
I do hereby agree to take part in this study. 
 
Patient           Name                       Signature                            Date 
(or Thumb impression) of the Subject/Legally Acceptable Representative 
Investigator   Name                      Signature                             Date 
Witness         Name                       Signature                            Date 
 
Annexure 2. Data sheet 
 
name hosp no age  sex indicatoin CMC 
INR 
test INR qc1 qc2 pt 
mumthaz 338985f 20 f dvt 4.04 3.2 10.1 29.6 31.8 
sujatha 354936f 20 f dvt 5.9 lo lo lo lo 
sujatha 354936f 20 f dvt 3.48 3.3 10.1 24.2 32.5 
balamuruli 828251c 22 m dvt 1.47 1.1 8.3 17.1 10.7 
bashirun 270948f 22 f dvt 4.75 3.9 12.9 21.9 39.1 
bashirun 270948f 22 f dvt 3.2 3.4 9.8 15 33.5 
balamuruli 828251c 22 m dvt 1.76 1.9 11 21.1 19 
balamuruli 828251c 22 m dvt 1.6 1.6 8.6 10.3 15.9 
bashirun 270948f 22 f dvt 1.78 er er er er 
balamuruli 828251c 22 m dvt 1.47 1.3 10.7 19.3 14.3 
balamuruli 828251c 22 m dvt 1.04 1.2 9.8 18.5 11.8 
bashirun 270948f 22 f dvt 1.37 1.4 10.1 18.6 14.2 
bashirun 270948f 22 f dvt 1.11 1.6 8.8 13.4 16.2 
bharati 822687d 25 f dvt 2.27 2.4 11.6 22.4 24.4 
pushparaj 087019d 25 m dvt 1.68 2 10.1 20.7 48.3 
bharati 822678d 25 f dvt 1.53 1.8 9.8 18.2 18.2 
tamilselvi 211676f 27 f dvt 1.06 1.1 9.8 21.8 23.6 
tamilselvi 211676f 27 f dvt 2.35 1.3 10.3 18.8 13.1 
tamilselvi 211676f 27 f dvt 1.68 1.8 11.9 20.6 17.8 
bishwa 283812f 28 m dvt 1.93 3.7 10.5 20.8 3.3 
bonnie 307670f 28 m dvt 2.21 2.1 10.5 17.8 21.1 
sridevi 177045f 29 f dvt 1.39 er er er er 
muniyan 291676f 29 m dvt 2.32 2.1 10.4 23.6 21.1 
gavaskar 020620c 30 m dvt 2.28 3.3 9.3 19.9 32.8 
satish 218318f 30 m dvt 1.47 1.6 10.8 16.5 15.9 
pownammal 240618f 30 f dvt 2.97 4 10.8 13.6 40.1 
satish 218318f 30 m dvt 2.15 2.4 10 17.8 23.5 
gandhi 895860d 31 m dvt 4.81 4.3 10.5 21.7 43 
laxmi 372675d 32 m art 2.33 2.7 11.9 21.5 27.3 
laxmi 372675d 32 m dvt 2.33 2.5 11.1 17.8 25 
ganesan 308740f 32 m dvt 1.09 1.3 12.9 11.2 17.2 
ganesan 308740f 32 m dvt 1.27 1.3 10.3 17.4 13.3 
laxmi  372675d 32 m dvt 0.99 0.8 11.3 18.7 8.3 
nabamita 243778f 32 f dvt 1.88 er er er er 
laxmi  372675d 32 m dvt 3.4 4 10.9 25 39.5 
laxmi 372675d 32 m art 2.33 4.5 11.3 20.4 23.7 
nabamita 243778f 32 f dvt 2.09 2.3 10.4 22.3 22.7 
laxmi 372675d 32 m dvt 2.38 2.6 9.6 16.6 19.5 
vijayakumar 272570d 33 m dvt 2.4 2.01 12 27.4 23.6 
kavitha 251784f 33 f dvt 1.59 1.6 11.3 19.4 15.5 
kavitha 251784f 33 f dvt 5.02 5.4 11.2 21.2 54.3 
kavitha 251784f 33 f dvt 1.99 2.1 9.8 25.1 21.2 
dhanabackiyam 647567b 34 f dvt 2.52 3.8 11.6 20.4 38.3 
dhinakaran 665782a 35 m dvt 2.82 2.2 8.4 17.3 21.1 
kasthoori 207887f 36 f dvt 2.06 2 9.3 14.5 20.1 
mahavishnu 002325f 37 m dvt 5.58 5.4 11.5 22.7 54.4 
mahavishnu 002325f 37 m dvt 1.26 1.6 11.2 19.9 15.7 
mahavishnu 002325f 37 m dvt 2.43 2.43 11.8 17.3 38.8 
siva 240672f 37 m dvt 3.1 3.3 9.9 18.2 32.7 
mahavishnu 002325f 37 m dvt 1.37 er er er er 
mahavishnu 002325f 37 m dvt 2.66 3.2 10.8 23.1 31.7 
mahavishnu 002325f 37 m dvt 1.8 1.7 10.8 16.2 18.6 
prasad 213249d 38 m art 1 1.3 8.2 14.6 13.3 
loganathan 207911f 39 m dvt 1 1.1 10.2 18.8 10.6 
manimaran 317705f 39 m dvt 3.17 7.5 9.4 21.2 hi 
vijalakshmi 295538f 40 f dvt 4 er er er er 
vijalakshmi 295538f 40 f dvt 2.12 1.6 8.7 17.3 16.1 
krishnamoorthy 316649f 40 m dvt 1 1.1 10.5 28.8 10.6 
vijayalakshmi 295538f 40 f dvt 2.14 2.1 9.1 18.4 20.6 
selvam 332419f 40 m dvt 2.01 2.4 11 21.2 24.1 
mathiyalagan 537279d 41 m dd 4.98 er er er er 
mathiyalagan 537279d 41 m dvt 1.68 2 10.1 19.7 23.3 
santhi 426298a 42 f dvt 1.7 2.7 11.5 20 27.4 
murali 186881f 42 m dvt 2.15 1.5 12.5 16.2 14.5 
shanthi 426298a 42 f dvt 2.29 2.9 10.7 25 28.5 
muurali 186881f 42 m dvt 4.15 4 11.7 23 44 
kanagalakshmi 995603c 43 f dvt 2.85 3.1 12.1 21 3.7 
damodaran 015112b 43 m dvt 4.12 3.7 10.2 22 36.6 
kanagalakshmi 995603c 43 f dvt 3.42 3.4 10.4 23 33.7 
jakeer 981899b 43 m dvt 1.44 1.5 10.1 16.3 14.8 
dhinakaran 665782a 44 m art 2.05 0.8 1.5 21.9 7.9 
dhinakaran 665782a 44 m art 1.33 1.4 10 18.4 13.7 
anbu 068453f 45 f dvt 2.1 2.5 10.1 14.7 24.7 
rajendran 359827d 46 m dvt 3.69 3.6 10.4 21.5 36.4 
shafeeulla 218634f 46 f dvt 2.32 2.3 10 15 23.1 
shafeeulla 218634f 46 m dvt 1.99 2.1 10.2 19.4 21 
shanthi 147616c 46 f art 2.8 3.2 11.2 20.2 31.7 
rajendran 359827d 46 m dvt 3.1 2.9 10.4 18.7 28.9 
sundari 003222f 46 f dvt 1.79 2 12.7 21.2 19.5 
venkatesan 172446f 47 m dvt 5.47 5.5 11.9 27.7 54.2 
venkatesan 172446f 47 m dvt 2.14 2.7 9.2 19.2 27.2 
muthumani 364833a 47 m dvt 2 2.5 11.9 19.7 25 
amara 259402f 47 f dvt 3.4 2.4 10.4 21.7 24.1 
renuka 335119f 47 f dvr 1.4 3.2 11.1 17.9 14.1 
renuka 335119f 47 f dvt 0.8 1.3 ,mn 18.7 13.1 
ammara 259402f 47 f dvt 3.01 2.2 10.3 13.7 22.2 
muthumani 364833a 47 f dvt 2.3 2.3 9.6 15.8 22.5 
renuka 335119f 47 f dvt 2.43 1.4 9.1 2.4 14.3 
rajendran 347416f 47 m dvt 2.82 2.2 10.6 22.7 21.5 
jagadish 351022f 47 m dvt 3.37 er er er er 
guna 105097d 48 m dvt 2.38 3.9 9.8 22.5 39 
rrenuka 335119f 48 f dvt 1.97 1.6 10.5 20.9 15.8 
vijaya 264482f 49 f dvt 1.26 er er er er 
jayakumar 118537 49 m dvt 2.3 2.06 10.6 15.3 22.5 
gauranga 277992f 49 m dvt 3.79 1 12.2 22 9.9 
jagatha 384313f 49 f art 1.1 1..8 11.5 19.1 17.9 
jagatha 384313f 49 f art 5.48 7.1 9.4 17.1 71.2 
indira 253000f 50 f dvt 1.7 1.7 12.3 20.9 17.4 
mangalakshmi 222885f 50 f dvt 3.48 er er er er 
indira 253000f 50 f dvt 1.5 er er er er 
indira 253000f 50 f dvt 1.8 1.9 10.4 22.8 14.4 
indira 253000f 50 f dvt 1.77 1.9 10.3 21.4 18.7 
indira 253000f 50 f dvt 1.98 1.6 10.6 23.4 14.4 
jothy 147840f 50 f dvt 2.47 2.1 10.7 21.1 20.8 
indira 253000f 50 f dvt 2.43 2.8 9.9 18.4 28 
kanchana 084314f 51 f dvt 2.52 2.5 214 11.3 24.1 
mangalakshmi 222885f 51 f dvt 1.7 2.2 10.3 13.7 22.2 
chengalrayalu 005057f 52 m dvt 0.97 0.9 13.3 26 8.6 
shakuntala 134933a 52 m dvt 2.38 2.2 10.4 19.1 22.3 
ravanamma 592409d 53 f dvt 2.88 3.9 9.6 17.5 38.8 
ram gopal 514251d 53 m art 2.01 2.2 11.8 22.5 22.3 
mani 264141f 54 m dvt 4.64 3.8 12.4 21.8 38.1 
mani 264141f 54 m dvt 1.07 2.01 11.7 17.3 19.8 
pradip 056275f 54 m dvt 1.04 1.3 12.4 21 12.5 
selvi 407641f 54 f dvt 3.16 3 12.4 18.6 26.1 
bhagvan 048920b 54 m dvt 2.62 3 11.8 20.7 30.6 
mani 264141f 54 m dvt 1 1.3 10.7 20.3 13.1 
rani 312700f 55 m dvt 1.7 5.2 12.4 24.8 51.7 
md jafar 171346f 57 m nephrotic 1.2 er er er er 
anjala 560947 57 f dvt 1.51 er er er er 
chakrabani 508949c 58 m dvt 2.41 2.7 11 21.7 27.1 
venkatesan 925518c 60 m dvt 1.7 1.8 9.9 18.4 18.3 
lalitha 726940c 61 f dvt 1.13 1.8 11.9 19.7 25 
subramaniaam 336635f 61 m dvt 1.24 1.2 10 14.8 11.8 
subramaniaam 336635f 61 m dvt 1.49 1.6 9.7 23.3 15.9 
subramaniaam 336635f 61 m dvt 4.63 5.3 10.8 21.5 63.1 
ramu 406126c 62 m dvt 1.58 1.9 9.9 17.6 18.9 
sree 066126a 62 f dvt 2.3 er er er er 
ramu 406126c 62 m dvt 1.24 er er er er 
chinna 274461f 63 f dvt 2.3 2.4 10.5 21 23 
savithri 941028d 64 f dvt 2.07 1.2 11.2 27.4 12.3 
selvaraj 894086d 65 m dvt 2.48 2.7 10.6 22.5 26.8 
kasiammal 304631f 65 f dvt 10 4.1 11.3 24.6 40.9 
manoharan 529289b 65 m dvt 1.93 2.1 9.5 17.4 21.1 
setty 174497f 66 m dvt 1.92 1.9 11.1 21.4 18.9 
baskaran 018197a 66 m dvt 2.16 2.2 12 20 22.4 
setty 174497f 66 m dvt 1.5 er er er er 
baskaran 018197a 66 m dvt 2.86 3.4 11 26.8 33.6 
setty 174497f 66 m dvt 2.99 hi hi hi hi 
narasimha 588068d 66 m dvt 5.08 5.8 10.3 19.8 57.5 
lakshmi kantaiah 168300f 67 m dvt 3.08 1.41 13.7 17.7 13.7 
sammpooornam 068976c 68 f dvt 2.05 2.52 11.5 19.3 24.6 
sammpooornam 068976c 68 f dvt 2.61 2.4 9.8 21.8 22.4 
selvaraj 871404a 69 m dvt 1.5 1.7 10.9 18.9 17.2 
saroja 533665c 69 f dvt 1.47 er er er er 
saroja 533665c 70 f dvt 1.77 2 10.3 15.2 19.8 
subramaniaam 384688f 70 m dvt 4.63 3.5 11.3 22.1 34.5 
amma 058168d 71 f dvt 1.5 1.8 9 14.8 18.2 
vendabai 280656f 75 f dvt 2.2 1.5 12.5 21.1 15.1 
amara 259402f 47 f dvt 2.82 2.8 9.9 16.6 27.9 
regina 468941d 43 f art 2.3 2.4 11 19.2 24.3 
kumaravel 140137f 36 m dvt 1.08 1.2 12.4 18.7 11.9 
santosh 3016141f 35 m dvt 3.06 2.6 12.4 18.6 26.1 
amara 259402f 47 f dvt 1.42 1.4 10.4 19.4 14.4 
subramaniaam 174497f 66 m dvt 3.01 3.1 11.5 12.5 30.8 
shanti 426298a 42 f dvt 3.99 3.5 10.7 21.7 21.4 
manoharan 529289b 65 m dvt 2.29 2.4 16.7 25.2 24.3 
balu   m dvt 2.27 2.6 10.6 23 25.9 
shanthi 147616c 46 f art 2.94 2.9 8.4 20.4 29.3 
narasimha 588068d 66 m dvt 3.48 4.8 10.4 20.7 48.3 
vendabai 280656f 75 f dvt 2 2.5 10.2 18.8 24.6 
shakuntala 134933a 52 f dvt 5.9 4 11.6 22.9 40 
reddy 588068d 66 m dvt 1.52 1.5 10.6 24.8 15.2 
shakuntala 134933a 52 f dvt 1.19 lo lo lo lo 
reddy 588068d 66 m dvt 1.52 1.5 10.6 24.8 15.2 
gopalakrishna 364466f 25 m dvt 4.66 4.5 11.7 23 44.9 
chinna 274461f 63 m dvt 1.05 0.8 9.7 18.1 8.4 
anbu 068453f 46 m dvt 2.66 2.1 12 16.4 21.4 
name hosp no low hb 
21/08/2012 
la 
9.1 
6.11.12 
30.11? 
thick skin 
low hb 
age  sex indicatoin times 
needed 
for 
result 
CMC 
INR 
test 
INR 
qc1 qc2 pt 
mumthaz 338985f 20 f dvt 1 4.04 3.2 10.1 29.6 31.8 
sujatha 354936f 20 f dvt 2 5.9 lo lo lo lo 
sujatha 354936f 20 f dvt 1 3.48 3.3 10.1 24.2 32.5 
balamuruli 828251c 22 m dvt 1 1.47 1.1 8.3 17.1 10.7 
bashirun 270948f 22 f dvt 2 4.75 3.9 12.9 21.9 39.1 
bashirun 270948f 22 f dvt 2 3.2 3.4 9.8 15 33.5 
balamuruli 828251c 22 m dvt 1 1.76 1.9 11 21.1 19 
balamuruli 828251c 22 m dvt 1 1.6 1.6 8.6 10.3 15.9 
bashirun 270948f 22 f dvt 2 1.78 er er er er 
balamuruli 828251c 22 m dvt 1 1.47 1.3 10.7 19.3 14.3 
balamuruli 828251c 22 m dvt 1 1.04 1.2 9.8 18.5 11.8 
bashirun 270948f 22 f dvt 1 1.37 1.4 10.1 18.6 14.2 
bashirun 270948f nephrotic 
low hb 
thick skin 
28/08/2012 
thick skin 
thick skin 
22 f dvt 1 1.11 1.6 8.8 13.4 16.2 
bharati 822687d 25 f dvt 1 2.27 2.4 11.6 22.4 24.4 
pushparaj 087019d 25 m dvt 1 1.68 2 10.1 20.7 48.3 
bharati 822678d 25 f dvt 1 1.53 1.8 9.8 18.2 18.2 
tamilselvi 211676f 27 f dvt 1 1.06 1.1 9.8 21.8 23.6 
tamilselvi 211676f 27 f dvt 1 2.35 1.3 10.3 18.8 13.1 
tamilselvi 211676f 27 f dvt 1 1.68 1.8 11.9 20.6 17.8 
bishwa 283812f 28 m dvt 1 1.93 3.7 10.5 20.8 3.3 
bonnie 307670f 28 m dvt 1 2.21 2.1 10.5 17.8 21.1 
sridevi 177045f 29 f dvt 2 1.39 er er er er 
muniyan 291676f 29 m dvt 1 2.32 2.1 10.4 23.6 21.1 
indrajit 120897d 30 m art 1 2.3 2.7 11.7 23.8 27.8 
gavaskar 020620c 30 m dvt 1 2.28 3.3 9.3 19.9 32.8 
satish 218318f 30 m dvt 1 1.47 1.6 10.8 16.5 15.9 
pownammal 240618f 30 f dvt 1 2.97 4 10.8 13.6 40.1 
satish 218318f 30 m dvt 1 2.15 2.4 10 17.8 23.5 
gandhi 895860d 31 m dvt 1 4.81 4.3 10.5 21.7 43 
laxmi 372675d 32 m art 1 2.33 2.7 11.9 21.5 27.3 
laxmi 372675d 32 m dvt 1 2.33 2.5 11.1 17.8 25 
ganesan 308740f 32 m dvt 1 1.09 1.3 12.9 11.2 17.2 
ganesan 308740f 32 m dvt 1 1.27 1.3 10.3 17.4 13.3 
laxmi  372675d 32 m dvt 1 0.99 0.8 11.3 18.7 8.3 
nabamita 243778f 32 f dvt 2 1.88 er er er er 
laxmi  372675d 32 m dvt 1 3.4 4 10.9 25 39.5 
laxmi 372675d 32 m art 1 2.33 4.5 11.3 20.4 23.7 
nabamita 243778f 32 f dvt 1 2.09 2.3 10.4 22.3 22.7 
laxmi 372675d 32 m dvt 1 2.38 2.6 9.6 16.6 19.5 
vijayakumar 272570d 33 m dvt 1 2.4 2.01 12 27.4 23.6 
kavitha 251784f 33 f dvt 1 1.59 1.6 11.3 19.4 15.5 
kavitha 251784f 33 f dvt 1 5.02 5.4 11.2 21.2 54.3 
kavitha 251784f 33 f dvt 1 1.99 2.1 9.8 25.1 21.2 
dhanabackiyam 647567b 34 f dvt 1 2.52 3.8 11.6 20.4 38.3 
sharmila 196250f 35 f dvt 1 4.79 5.3 12.3 21.5 36.4 
sharmila 196250f 35 f dvt 2 3.24 er er er er 
dhinakaran 665782a 35 m dvt 1 2.82 2.2 8.4 17.3 21.1 
kasthoori 207887f 36 f dvt 1 2.06 2 9.3 14.5 20.1 
mahavishnu 002325f 37 m dvt 1 5.58 5.4 11.5 22.7 54.4 
mahavishnu 002325f 37 m dvt 1 1.26 1.6 11.2 19.9 15.7 
mahavishnu 002325f 37 m dvt 1 2.43 2.43 11.8 17.3 38.8 
siva 240672f 37 m dvt 1 3.1 3.3 9.9 18.2 32.7 
mahavishnu 002325f 37 m dvt 1 1.37 er er er er 
mahavishnu 002325f 37 m dvt 1 2.66 3.2 10.8 23.1 31.7 
mahavishnu 002325f 37 m dvt 1 1.8 1.7 10.8 16.2 18.6 
prasad 213249d 38 m art 1 1 1.3 8.2 14.6 13.3 
loganathan 207911f 39 m dvt 1 1 1.1 10.2 18.8 10.6 
manimaran 317705f 39 m dvt 1 3.17 7.5 9.4 21.2 hi 
vijalakshmi 295538f 40 f dvt 2 4 er er er er 
vijalakshmi 295538f 40 f dvt 1 2.12 1.6 8.7 17.3 16.1 
krishnamoorthy 316649f 40 m dvt 1 1 1.1 10.5 28.8 10.6 
vijayalakshmi 295538f 40 f dvt 1 2.14 2.1 9.1 18.4 20.6 
selvam 332419f 40 m dvt 1 2.01 2.4 11 21.2 24.1 
mathiyalagan 537279d 41 m dd 2 4.98 er er er er 
mathiyalagan 537279d 41 m dvt 1 1.68 2 10.1 19.7 23.3 
santhi 426298a 42 f dvt 1 1.7 2.7 11.5 20 27.4 
murali 186881f 42 m dvt 1 2.15 1.5 12.5 16.2 14.5 
shanthi 426298a 42 f dvt 1 2.29 2.9 10.7 25 28.5 
muurali 186881f 42 m dvt 1 4.15 4 11.7 23 44 
kanagalakshmi 995603c 43 f dvt 1 2.85 3.1 12.1 21 3.7 
damodaran 015112b 43 m dvt 1 4.12 3.7 10.2 22 36.6 
kanagalakshmi 995603c 43 f dvt 1 3.42 3.4 10.4 23 33.7 
jakeer 981899b 43 m dvt 1 1.44 1.5 10.1 16.3 14.8 
dhinakaran 665782a 44 m art 1 2.05 0.8 1.5 21.9 7.9 
dhinakaran 665782a 44 m art 1 1.33 1.4 10 18.4 13.7 
anbu 068453f 45 f dvt 1 2.1 2.5 10.1 14.7 24.7 
rajendran 359827d 46 m dvt 1 3.69 3.6 10.4 21.5 36.4 
shafeeulla 218634f 46 f dvt 1 2.32 2.3 10 15 23.1 
shafeeulla 218634f 46 m dvt 1 1.99 2.1 10.2 19.4 21 
shanthi 147616c 46 f art 1 2.8 3.2 11.2 20.2 31.7 
rajendran 359827d 46 m dvt 1 3.1 2.9 10.4 18.7 28.9 
sundari 003222f 46 f dvt 1 1.79 2 12.7 21.2 19.5 
venkatesan 172446f 47 m dvt 1 5.47 5.5 11.9 27.7 54.2 
venkatesan 172446f 47 m dvt 1 2.14 2.7 9.2 19.2 27.2 
muthumani 364833a 47 m dvt 1 2 2.5 11.9 19.7 25 
amara 259402f 47 f dvt 1 3.4 2.4 10.4 21.7 24.1 
renuka 335119f 47 f dvr 1 1.4 3.2 11.1 17.9 14.1 
renuka 335119f 47 f dvt 1 0.8 1.3 ,mn 18.7 13.1 
ammara 259402f 47 f dvt 1 3.01 2.2 10.3 13.7 22.2 
muthumani 364833a 47 f dvt 1 2.3 2.3 9.6 15.8 22.5 
renuka 335119f 47 f dvt 1 2.43 1.4 9.1 2.4 14.3 
rajendran 347416f 47 m dvt 1 2.82 2.2 10.6 22.7 21.5 
jagadish 351022f 47 m dvt 2 3.37 er er er er 
saraswathy 987330d 48 f dvt 1 2.3 2.7 11.7 23.8 27 
guna 105097d 48 m dvt 1 2.38 3.9 9.8 22.5 39 
rrenuka 335119f 48 f dvt 1 1.97 1.6 10.5 20.9 15.8 
vijaya 264482f 49 f dvt 2 1.26 er er er er 
vijaya 264482f 49 f dvt 2 1.26 er er er er 
jayakumar 118537 49 m dvt 1 2.3 2.06 10.6 15.3 22.5 
gauranga 277992f 49 m dvt 1 3.79 1 12.2 22 9.9 
jagatha 384313f 49 f art 1 1.1 1..8 11.5 19.1 17.9 
jagatha 384313f 49 f art 1 5.48 7.1 9.4 17.1 71.2 
indira 253000f 50 f dvt 1 1.7 1.7 12.3 20.9 17.4 
mangalakshmi 222885f 50 f dvt 1 3.48 er er er er 
indira 253000f 50 f dvt 2 1.5 er er er er 
indira 253000f 50 f dvt 1 1.8 1.9 10.4 22.8 14.4 
indira 253000f 50 f dvt 1 1.77 1.9 10.3 21.4 18.7 
indira 253000f 50 f dvt 1 1.98 1.6 10.6 23.4 14.4 
jothy 147840f 50 f dvt 1 2.47 2.1 10.7 21.1 20.8 
indira 253000f 50 f dvt 1 2.43 2.8 9.9 18.4 28 
kanchana 084314f 51 f dvt 1 2.52 2.5 214 11.3 24.1 
mangalakshmi 222885f 51 f dvt 1 1.7 2.2 10.3 13.7 22.2 
chengalrayalu 005057f 52 m dvt 1 0.97 0.9 13.3 26 8.6 
shakuntala 134933a 52 m dvt 1 2.38 2.2 10.4 19.1 22.3 
ravanamma 592409d 53 f dvt 1 2.88 3.9 9.6 17.5 38.8 
ram gopal 514251d 53 m art 1 2.01 2.2 11.8 22.5 22.3 
mani 264141f 54 m dvt 1 4.64 3.8 12.4 21.8 38.1 
mani 264141f 54 m dvt 1 1.07 2.01 11.7 17.3 19.8 
mani 264141f 54 m dvt 1 1.6 1.6 11.3 19.7 164 
pradip 056275f 54 m dvt 1 1.04 1.3 12.4 21 12.5 
selvi 407641f 54 f dvt 1 3.16 3 12.4 18.6 26.1 
bhagvan 048920b 54 m dvt 1 2.62 3 11.8 20.7 30.6 
mani 264141f 54 m dvt 1 1 1.3 10.7 20.3 13.1 
rani 312700f 55 m dvt 1 1.7 5.2 12.4 24.8 51.7 
md jafar 171346f 57 m nephrotic 2 1.2 er er er er 
anjala 560947 57 f dvt 2 1.51 er er er er 
chakrabani 508949c 58 m dvt 1 2.41 2.7 11 21.7 27.1 
venkatesan 925518c 60 m dvt 1 1.7 1.8 9.9 18.4 18.3 
lalitha 726940c 61 f dvt 1 1.13 1.8 11.9 19.7 25 
subramaniaam 336635f 61 m dvt 1 1.24 1.2 10 14.8 11.8 
subramaniaam 336635f 61 m dvt 1 1.49 1.6 9.7 23.3 15.9 
subramaniaam 336635f 61 m dvt 1 4.63 5.3 10.8 21.5 63.1 
ramu 406126c 62 m dvt 1 1.58 1.9 9.9 17.6 18.9 
sree 066126a 62 f dvt 2 2.3 er er er er 
ramu 406126c 62 m dvt 2 1.24 er er er er 
chinna 274461f 63 f dvt 1 2.3 2.4 10.5 21 23 
savithri 941028d 64 f dvt 1 2.07 1.2 11.2 27.4 12.3 
selvaraj 894086d 65 m dvt 1 2.48 2.7 10.6 22.5 26.8 
kasiammal 304631f 65 f dvt 1 10 4.1 11.3 24.6 40.9 
manoharan 529289b 65 m dvt 1 1.93 2.1 9.5 17.4 21.1 
setty 174497f 66 m dvt 1 1.92 1.9 11.1 21.4 18.9 
baskaran 018197a 66 m dvt 1 2.16 2.2 12 20 22.4 
setty 174497f 66 m dvt 2 1.5 er er er er 
baskaran 018197a 66 m dvt 1 2.86 3.4 11 26.8 33.6 
setty 174497f 66 m dvt 1 2.99 hi hi hi hi 
narasimha 588068d 66 m dvt 1 5.08 5.8 10.3 19.8 57.5 
lakshmi 
kantaiah 
168300f 67 m dvt 1 3.08 1.41 13.7 17.7 13.7 
sammpooornam 068976c 68 f dvt 1 2.05 2.52 11.5 19.3 24.6 
sammpooornam 068976c 68 f dvt 1 2.61 2.4 9.8 21.8 22.4 
selvaraj 871404a 69 m dvt 1 1.5 1.7 10.9 18.9 17.2 
saroja 533665c 69 f dvt 2 1.47 er er er er 
saroja 533665c 70 f dvt 1 1.77 2 10.3 15.2 19.8 
subramaniaam 384688f 70 m dvt 1 4.63 3.5 11.3 22.1 34.5 
amma 058168d 71 f dvt 1 1.5 1.8 9 14.8 18.2 
vendabai 280656f 75 f dvt 1 2.2 1.5 12.5 21.1 15.1 
amara 259402f 47 f dvt 1 2.82 2.8 9.9 16.6 27.9 
regina 468941d 43 f art 1 2.3 2.4 11 19.2 24.3 
kumaravel 140137f 36 m dvt 1 1.08 1.2 12.4 18.7 11.9 
santosh 3016141f 35 m dvt 1 3.06 2.6 12.4 18.6 26.1 
amara 259402f 47 f dvt 1 1.42 1.4 10.4 19.4 14.4 
subramaniaam 174497f 66 m dvt 1 3.01 3.1 11.5 12.5 30.8 
manoharan 529289b 65 m dvt 1 10 er er er er 
shanti 426298a 42 f dvt 1 3.99 3.5 10.7 21.7 21.4 
manoharan 529289b 65 m dvt 1 2.29 2.4 16.7 25.2 24.3 
balu   m dvt  2.27 2.6 10.6 23 25.9 
shanthi 147616c 46 f art 1 2.94 2.9 8.4 20.4 29.3 
narasimha 588068d 66 m dvt 1 3.48 4.8 10.4 20.7 48.3 
vendabai 280656f 75 f dvt 1 2 2.5 10.2 18.8 24.6 
shakuntala 134933a 52 f dvt 1 5.9 4 11.6 22.9 40 
reddy 588068d 66 m dvt 1 1.52 1.5 10.6 24.8 15.2 
shakuntala 134933a 52 f dvt 2 1.19 lo lo lo lo 
reddy 588068d 66 m dvt 1 1.52 1.5 10.6 24.8 15.2 
gopalakrishna 364466f 25 m dvt 1 4.66 4.5 11.7 23 44.9 
chinna 274461f 63 m dvt 1 1.05 0.8 9.7 18.1 8.4 
anbu 068453f 46 m dvt 1 2.66 2.1 12 16.4 21.4 
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